Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

Nicacio.

The poster presented at the 2009 ASCO Annual Meeting is entitled: "A Phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (Stage III or IVa) inoperable head and neck cancer", by Reddy BK et al. (Citation: J Clin Oncol 27:15s, 2009; Abstract No: 6041; Session: Head and Neck Cancer; Type: General Poster Session; Time: Monday June 1, 8:00 AM to 12:00 PM; Location: Level 2, West Hall C). The trial was sponsored by Biocon Ltd., the licensee from CIMAB S.A. for nimotuzumab in India.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are ty
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Cambridge Semantics was one of just 22 companies ... Capitol Hill, hosted by The Data Transparency ... showcase how innovative data management applications can address the requirements ... , Originally introduced in 2011 by Committee Chairman ... Warner (D-VA ), the DATA Act is designed to ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... Switzerland (PRWEB) May 22, 2013 ... for industrial biotechnology, drug discovery, and life science ... Genedata Selector ™ as its bioinformatics platform ... production-relevant organisms. Genedata will provide AB Enzymes, one ... with a hosted solution of Genedata Selector accompanied ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4
... ST. JOSEPH, Mich., Oct. 2 GeneGo, Inc., the ... human,health care business unit of Akzo Nobel, have extended ... their MetaCore,license, Organon has also added MetaLink so that ... in the context of MetaCore,s manually,curated content. GeneGo ...
... and SHANGHAI, China, Oct. 2 HUYA ... focused,on the development of key disease-fighting drugs ... licensed a novel clinical stage anti-arrhythmic,compound from ... (SIMM),Chinese Academy of Sciences. The compound, ...
... Advanced Artificial Intelligence Software Is Cost-Effective, Time-Saving, ... today announced,the formal launch of CliniCom(TM), a ... and adults for possible,psychiatric conditions. CliniCom(TM), ... created for use in mental health settings, ...
Cached Biology Technology:Organon Extends MetaCore License and Adds MetaLink 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease that ... this pathogen has developed a complex method enabling it ... thus avoiding these acting against the infectious bacteria. , ... bioGUNE, in which teams from the National Institute of ... Centre in Barcelona (BSC) have also participated, has described ...
(Date:5/22/2013)... insects and wild plants have slowed in recent years, ... the University of Leeds and the Naturalis Biodiversity Centre ... in the diversity of species in Britain, Belgium and ... the picture brightened markedly after 1990, with a slowdown ... and wild plants. , Professor Bill Kunin, ...
(Date:5/21/2013)... device attached to a whale entangled in fishing gear, ... changed a whale,s diving and swimming behavior. The monitoring ... and migrate, depletes their energy as they drag gear ... slow death. , The scientists in this entanglement response ... two-year-old female North Atlantic right whale called Eg 3911. ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... The Institute for Micromanufacturing (IfM) at Louisiana Tech ... Science (CBERS) have joined forces to offer faculty fellowships ... and colleagues in other areas, particularly in the arts. ... professor of micro and nanosystems, one of the IfM,s ...
... Most running mammals totter along on their toes. In fact, ... like humans. Yet when it comes to long distance endurance ... up the miles, all be it inefficiently. So, why have ... the rest of our bodies are honed for marathon running? ...
... programs and courses have increased in recent years for ... study published in the 2010 volume of the ... researchers from Cornell University and North Carolina State University ... which are often a part of for-credit coursework, to ...
Cached Biology News:Louisiana Tech's Institute for Micromanufacturing to collaborate with colleagues in the arts 2Human use heel first gait because it is efficient for walking 2Hands-on: From classroom to employment 2
Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
... DNA and Gel Band Purification Kit, 100. For ... and DNA fragments (0.1-10 kb) from solution and ... DNA fragments from solution in as little as ... in 15 min.Prepacked glass fiber matrix columns provide ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Newborn Bovine Serum Heat-Inactivated...
Biology Products: